Gm8.5

Glucomannan

Glucomannan (Konjac Root Fiber)

A highly viscous soluble fiber from konjac root that promotes satiety, supports weight loss, and helps regulate blood sugar and cholesterol.

immunityfiberweight-losssatietycholesterol
Last reviewed: February 1, 2025
8.5/10
40+ studies
Evidence
moderate
Safety
1g three times daily before meals (3g total)
Dose
4-12 weeks
Time to Effect
Capsules (safest)
Best Form

Glucomannan is a water-soluble dietary fiber extracted from the root of the konjac plant (Amorphophallus konjac). It has an exceptional ability to absorb water - up to 50 times its weight - forming a thick gel in the stomach. This creates a strong sense of fullness, making it one of the most effective natural appetite suppressants. It also helps lower cholesterol and blood sugar by slowing nutrient absorption.

Mechanisms of Action

💧
Gel Formation

Absorbs water to form viscous gel

⏱️
Slowed Absorption

Slows carb and fat absorption

🦠
Prebiotic Effect

Feeds beneficial gut bacteria

Recommended Dose

1g three times daily before meals (3g total)

1g4g

Loading: Not required; consistent pre-meal dosing is key

Optimal Timing

  • 30-60 minutes before meals
  • With 1-2 glasses of water
  • Before largest meals for weight loss

Can be taken without food

Best Form

Capsules (safest)

Alternatives: Powder (must mix thoroughly), Konjac noodles (food form)

Capsules are safest to avoid choking. If using powder, mix well in water and drink immediately before it gels. Never take dry.

Duration

Minimum: 4 weeks

Optimal: 12 weeks

Cycling: Not required

Note: MUST be taken with plenty of water. Taking before meals creates satiety. Never take dry or with insufficient liquid.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

🍽️
Appetite Suppression

Strong feeling of fullness

30-60 minutes
80% of users notice thispositive
⚖️
Weight Loss

Modest but consistent weight reduction

4-8 weeks
65% of users notice thispositive
❤️
Cholesterol Reduction

Lowered LDL and total cholesterol

4-8 weeks
60% of users notice thispositive
⚠️
Choking Risk

Can expand and block throat if not taken properly

If improperly taken
5% of users notice thistrade-off
ModerateMax safe dose: 4g/day commonly used
🟡
Those seeking weight loss

One of the few supplements with proven weight loss effects

Who Should NOT Take This

  • Esophageal stricture or swallowing difficulties
  • GI obstruction

Drug Interactions

Diabetes medicationsmild

May enhance blood sugar lowering; monitor

Oral medicationsmild

May reduce absorption; take medications 1 hour before or 4 hours after

Possible Side Effects

Bloating and gascommon

Tip: Start with lower dose; increase gradually

Loose stoolsuncommon

Tip: Reduce dose

Esophageal obstructionuncommon

Tip: ALWAYS take with plenty of water; never take dry

Warnings

  • CHOKING HAZARD if not taken with enough water
  • Banned in some forms in certain countries due to choking risk
  • May interfere with medication absorption

Top studies from 40+ peer-reviewed papers

meta-analysisn=531
DOI

Sood N et al. • The American journal of clinical nutrition (2008)

“Glucomannan appears to beneficially affect total cholesterol, LDL cholesterol, triglycerides, body weight, and FBG, but not HDL cholesterol or BP.”
Key Findings:
  • Glucomannan appears to beneficially affect total cholesterol, LDL cholesterol, triglycerides, body weight, and FBG, but not HDL cholesterol or BP.
  • Published in The American journal of clinical nutrition (2008)
  • Further research warranted to confirm findings
rctn=112
DOI

Pokushalov E et al. • Nutrients (2024)

“Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms.”
Key Findings:
  • The experimental group showed significant reductions in body weight (treatment difference: -4.9%; 95% CI: -6.9% to -2.9%; p < 0.01) and BMI (treatment difference: -1.4 kg/m2; 95% CI: -1.7 to -1.2; p < 0.01) compared to placebo.
  • Further significant decreases in fat mass (treatment difference: -13.0%; 95% CI: -14.4 to -11.7; p < 0.01) and visceral fat rating (treatment difference: -1.3; 95% CI: -1.6 to -1.0; p < 0.01) were noted.
  • Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: -3.2%; 95% CI: -4.9% to -1.6%; p < 0.01) and BMI (treatment difference: -1.2 kg/m2; 95% CI: -2.0 to -0.4; p < 0.01) compared to heterozygous allele carriers.
  • These carriers also had a more significant reduction in fat mass (treatment difference: -9.8%; 95% CI: -10.6 to -9.1; p < 0.01) and visceral fat rating (treatment difference: -0.9; 95% CI: -1.3 to -0.5; p < 0.01).
meta-analysisn=6171
DOI

Shahinfar H et al. • Pharmacological research (2023)

“All rights reserved.”
Key Findings:
  • We conducted random-effects network meta-analysis with a Frequentist framework to estimate mean difference [MD] and 95% confidence interval [CI] of the effect of nutraceuticals on weight loss.
  • Supplementations with green tea (MD: -1.25 kg, 95%CI: -1.68, -0.82) and glucomannan (MD: -1.36 kg, 95%CI: -2.17, -0.54) demonstrated small weight loss, also the certainty of evidence was rated low.
  • Based on our findings, supplementations with nutraceuticals can result in a small weight loss in adults with overweight or obesity.Copyright © 2023 The Authors.
  • Published by Elsevier Ltd..
meta-analysisn=440
DOI

Zhang Z et al. • Nutrients (2023)

“Our analysis indicates that glucomannan is an effective nutritional intervention for type II diabetes.”
Key Findings:
  • We searched databases including PubMed, Cochrane, the comprehensive biomedical research database (Embase), Web of Science, and China National Knowledge Infrastructure (CNKI) for literature on glucomannan and type II diabetes.
  • Six randomized controlled trials (RCTs) were eligible (n = 440 participants) to be included in our analysis.
  • Our analysis indicates that glucomannan is an effective nutritional intervention for type II diabetes.
meta-analysisn=370
DOI

Ho HVT et al. • The American journal of clinical nutrition (2017)

“This study was registered at clinicaltrials.gov as NCT02068248.© 2017 American Society for Nutrition.”
Key Findings:
  • Data were pooled by using the generic inverse-variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs.
  • KJM significantly lowered LDL cholesterol (MD: -0.35 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19 mmol/L).
  • Data from 6 trials suggested no impact of KJM on apolipoprotein B.Conclusions: Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively.
40
Total Studies
8.4/10
Avg Quality
10-6,171
Sample Size Range
2005-2025
Research Span

Study Type Distribution

RCT
23
Meta-Analysis
9
Systematic Review
4
Crossover
3
In Vitro
1

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.